Centocor to launch Myoscint myocardial infarction imaging agent in early 1997.
This article was originally published in The Gray Sheet
Executive Summary
CENTOCOR MYOSCINT CARDIAC IMAGING AGENT EXPECTED TO LAUNCH IN EARLY 1997 following approval of the murine monoclonal antibody product in July. Myoscint is indicated for "preparation of Indium In 111 imciromab pentetate to be used as a cardiac imaging agent for detecting the presence and/or identifying the location of myocardial injury in patients with suspected myocardial infarction," FDA's July 3 approval letter states. Myoscint in vivo localizes in infarcted myocardial tissues.